Ascletis Pharma (China) Co. Ltd. has patented new 2-phenyl-1,2,4-triazine-3,5(2h,4h)-dione derivatives acting as thyroid hormone receptor β (THR-β) agonists potentially useful for the treatment of diabetes, obesity, hyperlipidemia, fibrosis, hepatic steatosis, thyroid cancer and hypercholesterolemia, among others.